Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: betty moyers who wrote (21679)	5/6/1999 8:57:00 AM
From: James Baker	Read Replies (3) \| Respond to of 23519

here is what all VIVUS longs have been waiting for! Company Press Release Clinical Study Confirms That MUSE Offers Second Chance for Patients Unsuccessful With Viagra 65% of Viagra Failures Choose To Use MUSE DALLAS--(BW HealthWire)--May 6, 1999--Tulane University School of Medicine today reported data at the 94th annual meeting of the American Urologic Association confirming the safety and efficacy of MUSE® (alprostadil) in patients who were unsuccessful with Viagra® (sildenafil citrate) due to lack of efficacy or side effects of treatment. ''In my practice, I have found that for many men with erectile dysfunction Viagra is either contraindicated or ineffective. MUSE is the ideal alternative for these patients,'' stated Dr. Wayne J.G. Hellstrom, Professor of Urology, Tulane University School of Medicine, and lead author of the abstract titled ''Efficacy of MUSE In Patients with Erectile Dysfunction Who Failed Viagra Therapy: Results From a Multicenter Post-Marketing Study.'' The study evaluated patients who had failed to respond to Viagra or who had experienced side effects resulting in discontinuation of Viagra. The study enrolled 367 patients at 73 clinical sites, and 285 patients completed the end-of-study-questionnaire. At the conclusion of the eight-week study, 71% of patients reported improvement in their erections with MUSE. Sixty-five percent of patients chose to continue using MUSE as their erectile dysfunction therapy. MUSE® (alprostadil) is marketed and distributed in the United States by VIVUS, Inc. (Nasdaq:VVUS - news). Viagra® (sildenafil citrate) is marketed and distributed in the United States by Pfizer, Inc. (NYSE: PFE - news).